EXACT Sciences — Technical Presentation (October 2010)
29 slides from EXACT Sciences's technical presentation, Oct 28, 2010
Slide 1: Presentation of Validation Study Results
Presentation of Validation Study Results October 28, 2010
Slide 2: Safe Harbor Statement
Certain matters contained in this presentation, other than historical information, consist of forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 relating to, among other things, our expectations concerning the timing of pote
Slide 3: Agenda
Agenda 2 News and Background About the Test About the Study Study Results Next Steps News and Background About the Test About the Study Study Results Next Steps
Slide 4: Validation Study Overview
Validation Study Overview 3 Overall purpose of study was to validate the company’s colorectal cancer and pre-cancer screening test panel The study was a part of an overall process of technology development and marker selection Validation study included a specificity study, followed by training and t
Slide 5: Summary of Validation Study Results
Summary of Validation Study Results 4 85% sensitivity cancer 64% sensitivity pre-cancer (>1cm) Combined Training & Test Sets 88% specificity News and Background About the Test About the Study Study Results Next Steps
Slide 6: Clinical Significance of Study Results
Clinical Significance of Study Results Cologuard™ assay has real potential as a colorectal cancer screening tool No non-invasive product exists that can detect 60% of pre-cancerous polyps Test may assist gastroenterologists in finding more pre-cancerous polyps and colorectal cancers Simple, affordab
Slide 7: Non-Invasive Colorectal Cancer Detection is Difficult
Non-Invasive Colorectal Cancer Detection is Difficult Long road to positive results Marker challenges: methylation markers are key Technology challenges: most detection methods won’t work reliably QuARTS™ technology is a big deal Challenging DNA extraction from stool Other non-invasive (fecal blood
Slide 8: The Exact Sciences' Solution: Distinct Pathways
The Exact Sciences’ Solution: 3 Distinct Pathways DNA methylation markers DNA mutation markers Hemoglobin marker Single Test Result If positive, refer to colonoscopy + + News and Background About the Test About the Study Study Results Next Steps 7
Slide 9: Methodical Product Development Approach
Methodical Product Development Approach 8 Sequencing Study Tissue Study Pilot Study Specificity Study Training Set Test Set 32 methyl. Markers Narrowed markers to 9 Unpublished data Generated IP on methylation markers 9 markers With 4-marker subset, 100% of cancers and pre-cancers detected at 100% s
Slide 10: Validation Study Overview
Validation Study Overview 9 Goal of study was to validate technology, marker selection and evaluate clinical performance prior to beginning pivotal clinical trial 1,178 stool samples processed and analyzed Study conducted at Exact Sciences and Mayo Clinic All training and test set samples were blind
Slide 11: Validation Study Samples
Validation Study Samples 10 Tough samples to find: Exact had access to rare samples Five different collection & storage protocols Samples collected and stored at -80°C over last 7 years Varying stool processing protocols by site Preservative-to-stool dilution ratio varied from ~8:1 to 4:1 Sample pro
Slide 12: Overall Study Results
Overall Study Results 11 85% sensitivity cancer 64% sensitivity pre-cancer Overall Study Results 88% specificity News and Background About the Test About the Study Study Results Next Steps
Slide 13: Pilot Study Results
Submitted data to AACR on August 23, 2010 Pilot Study 12 85% sensitivity cancer 55% sensitivity pre-cancer Pilot Study Results: with 3 markers 90% specificity News and Background About the Test About the Study Study Results Next Steps Test 118 samples 59 normal 29 adv adenomas 30 cancers
Slide 14: Specificity Study
Specificity Study Tested 500 samples to determine biases introduced by: Age Gender Ethnicity Geography Learned only age-related methylation bias occurs Developed age-related logistic regression Data assisted in setting methylation marker cutoffs 13 News and Background About the Test About the Study
Slide 15: Training Set Results
Establish cutoff Training Set Results 14 89% sensitivity cancer 64% sensitivity pre-cancer Training Set Results 89% specificity News and Background About the Test About the Study Study Results Next Steps
Slide 16: Test Set Results
Independently assess test performance Test Set Results 15 78% sensitivity cancer 64% sensitivity pre-cancer Test Set Results 85% specificity News and Background About the Test About the Study Study Results Next Steps
Slide 17: Sensitivity by Cancer Stage
Sensitivity by Cancer Stage 16 News and Background About the Test About the Study Study Results Next Steps Sensitivity (%) Cancer Stage
Slide 18: Sensitivity by Adenoma Size
Sensitivity by Adenoma Size 17 News and Background About the Test About the Study Study Results Next Steps Sensitivity (%) Adenoma Size (cm)
Slide 19: Sensitivity by Lesion Site
Sensitivity by Lesion Site 18 News and Background About the Test About the Study Study Results Next Steps Sensitivity (%) Proximal (Right) Distal (Left) Cancer Pre-Cancer
Slide 20: Overview of Validation Study Samples
Overview of Validation Study Samples 19 Table 1: Participant and Lesion Characteristics
Slide 21: Technical Significance of Study Results
Technical Significance of Study Results First non-invasive test to detect > 50% of pre-cancerous polyps and 85% of cancers with high specificity Demonstration of QuARTS™ technology as a superior method to detect both methylation and mutation markers Selection and validation of a multi-marker panel S
Slide 22: Clinical Significance of Study Results
Clinical Significance of Study Results Cologuard™ assay has real potential as a colorectal cancer screening tool No non-invasive product exists that can detect 60% of pre-cancerous polyps Test may assist gastroenterologists in finding more pre-cancerous polyps and colorectal cancers Simple, affordab
Slide 23: What Can Be Improved?
What Can Be Improved? Product Sample Study QC processes and assay reproducibility Improve DNA capture efficiency Improve mutation assays Improve hemoglobin detection Optimize multiplex methylation assays Single collection device Consistent buffer-to-stool dilution ratio Consistent stool processing p
Slide 24: Exact Sciences' Next Steps
Exact Sciences’ Next Steps 23 DNA extraction Detection assay Finalize collection kit GMP manufactured product Validated reagents News and Background About the Test About the Study Study Results Next Steps Work with FDA and CMS to finalize Narrow list of agencies’ questions Enroll sites Side studies
Slide 25: Conclusions
Conclusions Tremendous results in achieving targets Strong pre-cancer detection Identified areas to improve product and clinical trial design Potential to improve clinical outcomes Achieved goals of validating assay, technology and markers 24 News and Background About the Test About the Study Study
Slide 26: Acknowledgements
Thank you to the Mayo Clinic and Exact Sciences employees. Thanks also to Dr. Bert Vogelstein, Dr. Sandy Markowitz, Rob Cascella and Stan Lapidus. This company’s progress would not be possible without them.
Slide 27: Questions & Answers
Questions & Answers eG exact
Slide 28: Appendix
Appendix eG exact
Slide 29: The Colon Cancer Epidemic
The Colon Cancer Epidemic 28 150,000 new cases in U.S. 50,000 deaths in U.S. 600,000 deaths worldwide Source: ACS: Cancer Facts and Figures 2008 Ovary Prostate Pancreas Breast Colorectal Lung Cervix 15,520 28,660 34,290 40,930 49,960 159,390 3,870 U.S. Annual Cancer Mortality
Exact Sciences — Technical Presentation (October 2010) on 6ix